Our 2017 agenda is still in the works, but in the meantime, here's a look at what our 2016 event had to offer!




3D Antibody Modeling

  • How models have changed between the two assessments
  • What models can do for therapeutic research
  • Modeling an unknown target


Lessons from Ebola - Pandemic preparedness and antibodies against infectious diseases

  • What are the benefits and concerns surrounding plasma transfusion technology
  • How does the antibody therapy delivered in this manner differ from lab-made antibodies
  • Downstream considerations for plasma transfusion approach


New innovations in ADC payloads: a new class to improve efficacy

  • Comparing this new class to previous innovations
  • Varying potency through linker selection
  • Importance of conjugation chemistry in ADC design


Addressing translational questions in ADC design

  • Understanding the impact of ADC design choices on therapeutic index
  • Connecting antigen and tumor characteristics to sensitivity to ADCs
  • Connecting short-term and long-term responses to ADCs using mathematical modeling


How sampling and characterization of human antigens changes how we produce therapeutic antibodies

  • Antibody characterization in vaccine research
  • Development of therapeutic antibodies for infectious diseases
  • How the interface between vaccine and antibody research is integral to success





Get involved

If you'd like to become an exhibitor or sponsor at the event,
contact Chris Hackett
on tel: +1 646 619 1803 or